Security
Aktis Oncology, Inc. Common stock · AKTS
AKTSNASDAQCommon stockCurrentCIK 2035832Updated Oct 3, 2026
AKTS price & chart
Loading TradingView…
NASDAQ:AKTS on TradingView ↗About the company
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure pa…
In the news
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors ↗
Recent filings
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
144 filing
Show 5 more recent filings
Offerings
Registration 333-292283
- Gross proceeds
- 317700000.0
- Net proceeds
- 295461000.0
- Deal price
- 18.0
- Shares
- 17650000
- Offering price
- $18.00
- Ticker
- AKTS
Filing attachments
ck0002035832-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors • Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer (mUC) and other Nectin-4 expressing solid tumors …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026 • Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments • Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 • Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026…
Read attachment ↗d110479dex991.htm · 8-K · 2026-04-16
EX-99.1 2 d110479dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors BOSTON - April 16, 2026 - Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results • Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations • Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSW…
Read attachment ↗d875386dex41.htm · S-1 · 2025-12-19
EX-4.1 8 d875386dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 20, 2024, by and among Aktis Oncology, Inc…
Read attachment ↗